The price tag of a potential cure for chronic hepatitis B infection: A cost threshold analysis for USA, China and Australia,Liver International

当前位置： X-MOL 学术 › Liver Int. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

The price tag of a potential cure for chronic hepatitis B infection: A cost threshold analysis for USA, China and Australia
Liver International ( IF 6.7 ) Pub Date : 2021-07-30 , DOI: 10.1111/liv.15027
Mehlika Toy ₁ , David Hutton ₂ , Karen McCulloch _{3,

4} , Nicole Romero _{3,

5} , Peter A Revill _{6,

7} , M-Capucine Penicaud ₈ , Samuel So ₁ , Benjamin C Cowie _{3,

5,

9}

Affiliation

Asian Liver Center, Department of Surgery, Stanford University School of Medicine, Palo Alto, California, USA.
Department of Health Management and Policy, University of Michigan, Ann Harbor, MI, USA.
WHO Collaborating Centre for Viral Hepatitis, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Epidemiology Unit, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia.
Department of Medicine (Royal Melbourne Hospital), Faculty of Medicine, Dentistry, and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia.
Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Department of Microbiology and Immunology, University of Melbourne, Parkville, Victoria, Australia.
The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, Victoria, Australia.

We aim to capture the economic impact of a potential cure for chronic hepatitis B infection (CHB) in three countries (USA, China and Australia) with different health systems and epidemics to estimate the threshold drug prices below which a CHB cure would be cost-saving and/or highly cost-effective.

更新日期：2021-07-30

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>